|
EP2771332A1
|
|
Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
|
|
WO2013062882A1
|
|
Scd inhibitors for the treatment of hcv
|
|
AU2012204063A1
|
|
Aminopyrimidines as Syk inhibitors
|
|
WO2012055031A1
|
|
Hiv protease inhibitors
|
|
WO2012055034A1
|
|
Sulfonamides as hiv protease inhibitors
|
|
RS54017B1
|
|
Non-nucleoside reverse transcriptase inhibitors
|
|
UA108495C2
|
|
Reverse transcriptase nucleoside inhibitors
|
|
AU2011224710A1
|
|
Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials
|
|
EP2445872A1
|
|
Cathepsin cysteine protease inhibitors for the treatment of various diseases
|
|
EP2398796A1
|
|
Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
|
|
AU2010215035A1
|
|
Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
|
|
EP2373306A1
|
|
Transdermally administered aliskiren
|
|
AU2009295308A1
|
|
Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists
|
|
EP2344497A1
|
|
Azaindole derivatives as crth2 receptor antagonists
|
|
EP2334666A1
|
|
Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
|
|
EP2148878A1
|
|
Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
|
|
EP2139876A1
|
|
Cathepsin cysteine protease inhibitors
|
|
AU2007260529A1
|
|
Indoline amide derivatives as EP4 receptor ligands
|
|
AU2007242018A1
|
|
Indole amide derivatives as EP4 receptor antagonists
|
|
EP1902031A1
|
|
Cathepsin cysteine protease inhibitors
|
